<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147355</url>
  </required_header>
  <id_info>
    <org_study_id>ESPRIT TOXIL-2 UNSW PSO 6361</org_study_id>
    <secondary_id>ACTR012605000407695</secondary_id>
    <nct_id>NCT00147355</nct_id>
  </id_info>
  <brief_title>Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy</brief_title>
  <official_title>An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This substudy is an open-label, randomised study comparing the uptake of recombinant
      interleukin-2 (rIL-2) in HIV-1 infected individuals receiving different combinations of
      antiemetics and analgesic agents during rIL-2 dosing in ESPRIT. The design is a factorial one
      with 4 arms. All patients will receive regular ibuprofen and paracetamol from days 1-6 of the
      rIL-2 dosing cycle; in addition, patients will be randomised to receive one of two antiemetic
      combinations, i.e. ondansetron or metoclopramide with or without low dose codeine phosphate
      as an additional analgesic agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research is a randomised open-label substudy of ESPRIT. The substudy is exploring whether
      the amount of rIL-2 taken during a dosing cycle of rIL-2 can be increased through controlling
      the predictable side-effects of rIL-2 better. This is a four arm study with a factorial
      design; patients will be randomised to one of four arms. Each arm consists of different
      combinations of adjunctive agents. Each patient will receive paracetamol and ibuprofen
      prophylactically throughout the cycle, the other adjunctive agents prescribed will vary
      according to which arm the patient is randomised to, but the antiemetic used will be either
      ondansetron or metoclopramide with or without low dose codeine phosphate as an additional
      analgesic agent. The primary end-point is the percentage of planned rIL-2 actually taken
      during the cycle. Secondary end-points include safety, side-effects of rIL-2 and the
      adjunctive agents, CD4+ T-cell changes and quality of life measures.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    28 of 168 patients only were enrolled, numbers too low to be conclusive
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of planned rIL-2 taken during the first rIL-2 dosing cycle while participating in this substudy.</measure>
    <time_frame>6 months</time_frame>
    <description>we are comparing the percentage of planned rIL-2 taken when randomised to one of the four combinations used as adjunctive therapies to alleviate the known side-effects of rIL-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of rIL-2 cycling frequency in the six months after randomisation into the substudy</measure>
    <time_frame>6 months</time_frame>
    <description>to explore the patterns of rIL-2 and see if the different adjuntive regimens increase tolerability such that more rIL-2 is taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of planned rIL-2 taken during the cycles after the first cycle</measure>
    <time_frame>6 mths</time_frame>
    <description>this is to assess whether the adjuncts to which the patient was randomised as part of this substudy impact on better tolerability of cycles of rIL-2 beyond the first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in rIL-2 taken during each cycle in the six-month period following randomisation into this substudy and rIL-2 uptake during the last dosing cycle immediately prior to participation in the substudy</measure>
    <time_frame>6 months</time_frame>
    <description>to see if the adjuncts to which the patient is randomised improve amount of rIL-2 taken compared to the cycle taken prior to enrollment in this substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with dose modifications during the cycle due to toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>to assess whether the adjuncts to which they were randomised reduced the amount of rIL-2 dose modification during the rIL-2 cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade 1-4 constitutional upset (defined as any or all of the following: flu-like illness/fever/myalgia/arthralgia/headache) and/or GI upset and/or evidence of capillary leak syndromes</measure>
    <time_frame>6 months</time_frame>
    <description>to assess the impact of the randomised adjuntive agents on the predictable side-effects of rIL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 1-4 creatinine and sodium changes during and after rIL-2 dosing;</measure>
    <time_frame>6 months</time_frame>
    <description>to assess the impact of the randomised adjuntive agents on the predictable effects of rIL-2 in regards to salt and water homeostasis and renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life during and after rIL-2</measure>
    <time_frame>6 months</time_frame>
    <description>to assess whether the use of different adjunctive agents impacted on the tolerability of rIL-2 during the cycle and post as perceived by the patients qOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAE and AE</measure>
    <time_frame>6 months</time_frame>
    <description>to assess the incidence of SAE and AEs that are rIL-2 (captured for the main study) and adjunctive agents</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron, ibuprofen, paracetamol</intervention_name>
    <description>ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron, ibuprofen, paracetamol</intervention_name>
    <description>Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide, ibuprofen, paracetamol</intervention_name>
    <description>metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide, codeine phosphate, ibuprofen, paracetamol</intervention_name>
    <description>metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients participating in ESPRIT and randomised to the rIL-2 arm, who:

          1. Are not at CD4+ T-cell target for the protocol

          2. Have not received rIL-2 for &gt; 2 months

          3. Have reported both GI upset and constitutional side-effects as one of the reasons for
             either dose modifying in prior cycles or unwillingness to receive further rIL-2

          4. Are considered by the Investigator as medically safe to receive further dosing with
             rIL-2

          5. Are willing to receive further dosing with rIL-2 at the dose specified by the
             Investigator

          6. Are willing to sign informed consent to participate in the substudy

        Exclusion Criteria:

          1. All exclusions for the receipt of rIL-2 on ESPRIT

          2. Known allergy to non-steroidal anti-inflammatory drugs (NSAIDs), opiates, 5HT-3
             (serotonin-3) inhibitors, anti-dopaminergic antiemetics, or any other components of
             the proposed adjunct regimens.

          3. Use of other NSAIDs (cyclooxygenase-2 [COX-2] inhibitors, corticosteroids) or opiate
             analgesics within two weeks of rIL-2 dosing. Use of low dose aspirin as a
             cardio-protective agent is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah L Pett, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, Faculty of Medicine, University of New South Wales, Sydney, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Agudos JM Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C221</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUNCEI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Prof. Alejandro Posadas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal de Agudos San Juan de Dios</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal General de Agudos Oscar Alende</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Medical Unit</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairns Base Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Sexual Health Clinic</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nambour Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlton Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rIL-2-toxicity</keyword>
  <keyword>interleukin-2 therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Toxicity substudy of ESPRIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Codeine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

